Abstract
In order to best care for women, obstetrician-gynecologists (ob-gyns) must be able to diagnose and treat sexually transmitted infections (STIs), as well as effectively communicate risks regarding STIs. This article provides a narrative review of studies primarily conducted by the Research Department at the American College of Obstetricians and Gynecologists, about missed opportunities for STI risk communication. Missed opportunities include the omission or partial completion of STI risk assessment and counseling, failure to offer screening or testing, lack of follow-up on STI testing/vaccination refusals, and a failure to comply with existing guidelines. We also discuss knowledge level, time constraints, and gaps in statistical literacy as barriers to STI communication. The aim of this article is to highlight common barriers to risk communication, discuss their potential impact, and suggest means by which these obstacles can be addressed. Future directions for training, education, and research are discussed.
Keywords: Barriers, HCV, HIV, HPV, obstetrician-gynecologists, risk communication, screening, sexually transmitted infections, vaccination.
Current HIV Research
Title:Obstetrician-Gynecologists’ Practices, Statistical Literacy, and Risk Communication with Regard to Sexually Transmitted Infections
Volume: 13 Issue: 5
Author(s): Meaghan A. Leddy, Britta L. Anderson and Jay Schulkin
Affiliation:
Keywords: Barriers, HCV, HIV, HPV, obstetrician-gynecologists, risk communication, screening, sexually transmitted infections, vaccination.
Abstract: In order to best care for women, obstetrician-gynecologists (ob-gyns) must be able to diagnose and treat sexually transmitted infections (STIs), as well as effectively communicate risks regarding STIs. This article provides a narrative review of studies primarily conducted by the Research Department at the American College of Obstetricians and Gynecologists, about missed opportunities for STI risk communication. Missed opportunities include the omission or partial completion of STI risk assessment and counseling, failure to offer screening or testing, lack of follow-up on STI testing/vaccination refusals, and a failure to comply with existing guidelines. We also discuss knowledge level, time constraints, and gaps in statistical literacy as barriers to STI communication. The aim of this article is to highlight common barriers to risk communication, discuss their potential impact, and suggest means by which these obstacles can be addressed. Future directions for training, education, and research are discussed.
Export Options
About this article
Cite this article as:
Leddy A. Meaghan, Anderson L. Britta and Schulkin Jay, Obstetrician-Gynecologists’ Practices, Statistical Literacy, and Risk Communication with Regard to Sexually Transmitted Infections, Current HIV Research 2015; 13 (5) . https://dx.doi.org/10.2174/1570162X13666150511141942
DOI https://dx.doi.org/10.2174/1570162X13666150511141942 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Protein Degradation in the Nervous System
Current Medicinal Chemistry - Central Nervous System Agents PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Drug Metabolism and Individualized Medicine
Current Drug Metabolism Immunomodulatory and Anti-inflammatory Properties of Artesunate in Experimental Colitis
Current Medicinal Chemistry Macromolecular Drug Targets in Cancer Treatment and Thiosemicarbazides as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Potential of Essential Oil-based Microemulsions: Reviewing State-of-the-art
Current Drug Delivery Molecular Imaging to Monitor Repair of Myocardial Infarction Using Genetically Engineered Bone Marrow-Derived Mesenchymal Stem Cells
Current Gene Therapy Targeting Therapeutic and Imaging Agents to Folate Receptor Positive Tumors
Current Pharmaceutical Biotechnology A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort
Current Drug Metabolism <i>In Silico</i> Docking of Anti Cancerous Drugs with β-Cyclodextrin polymer as a Prominent Approach to Improve the Bioavailability
Anti-Cancer Agents in Medicinal Chemistry Jatropha curcas: From Biodiesel Generation to Medicinal Applications
Recent Patents on Biotechnology Medicinal Research Progress of Natural Coumarin and its Derivatives
The Natural Products Journal Targeting Protein Degradation in Cancer Treatment
Current Chemical Biology Involvement of Lanthanides in the Free Radicals Homeostasis
Current Topics in Medicinal Chemistry New Issues for Copper-64: from Precursor to Innovative Pet Tracers in Clinical Oncology
Current Radiopharmaceuticals Oxazole-Based Compounds As Anticancer Agents
Current Medicinal Chemistry Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents
Recent Patents on Anti-Cancer Drug Discovery